GlassScriptPhysician profile
Karam C Mounzer
NPI 1265571152
$711,871.64
in general payments reported to CMS, 2019-2025
16 companies · $117K in 2025
The $117K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165K · 2020: $99K · 2021: $65K · 2022: $91K · 2023: $82K · 2024: $93K · 2025: $117K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $203K · Consulting Fee: $56K · Travel and Lodging: $18K · Food and Beverage: $12K · Honoraria: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $202,942.50 |
| Consulting Fee | $55,820.00 |
| Travel and Lodging | $17,898.05 |
| Food and Beverage | $12,144.59 |
| Honoraria | $2,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $320,714.75 | 2019-2025 | Rukobia, Dovato, Cabenuva |
| Gilead Sciences, INC. | $242,615.61 | 2019-2025 | Biktarvy, Yeztugo, Sunlenca |
| Janssen Products, LP | $78,385.56 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $39,899.46 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Theratechnologies INC. | $14,216.77 | 2019-2025 | Trogarzo, Egrifta |
| Janssen Scientific Affairs, LLC | $9,994.67 | 2020-2023 | Symtuza |
| Glaxosmithkline, LLC. | $4,708.17 | 2022 | |
| Janssen Biotech, INC. | $764.95 | 2019-2023 | Symtuza |
| Abbvie INC. | $334.94 | 2019-2025 | |
| Hologic Sales and Service, LLC | $79.84 | 2021-2022 | |
| Indivior INC. | $55.10 | 2024-2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $35.00 | 2023 | Symtuza |
| Mylan Institutional INC. | $29.17 | 2019 | |
| Emd Serono, INC. | $19.22 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.43 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karam Mounzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.